Dantrolene low-volume - Eagle Pharmaceuticals

Drug Profile

Dantrolene low-volume - Eagle Pharmaceuticals

Alternative Names: Dantrolene; Dantrolene sodium; EP-4104; Ryanodex

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Lyotropic Therapeutics
  • Developer Eagle Pharmaceuticals
  • Class Antispastics; Furans; Hydantoins; Imidazolidines; Muscle relaxants; Nitrophenols; Small molecules
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fever; Wounds
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fever
  • Preregistration Wounds

Most Recent Events

  • 21 Jun 2017 Eagle Pharmaceuticals plans a phase II trial for Drug toxicity (Adjuvant therapy) (NCT03189433)
  • 27 Mar 2017 Dantrolene low-volume receives priority review status for Wounds (Exertional heat stroke) in USA
  • 27 Mar 2017 FDA assigns PDUFA action date of (23/07/2017) for dantrolene low-volume for Wounds (Exertional heat stroke) (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top